Literature DB >> 26088928

The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.

Clodagh Keohane1, Donal P McLornan2, Katy Sanchez3, Christopher Connor3, Deepti Radia3, Claire N Harrison3.   

Abstract

Entities:  

Keywords:  Janus kinases; blood platelets; primary myelofibrosis; thrombosis

Mesh：

Substances：

Year:  2015        PMID： 26088928      PMCID： PMC4800696          DOI： 10.3324/haematol.2015.128918

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

1.  Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients.

Authors:  C Besses; F Cervantes; A Pereira; L Florensa; F Solé; J C Hernández-Boluda; S Woessner; J Sans-Sabrafen; C Rozman; E Montserrat
Journal:  Leukemia       Date:  1999-02       Impact factor: 11.528

2.  Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.

Authors:  M K Jensen; P de Nully Brown; B V Lund; O J Nielsen; H C Hasselbalch
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

3.  Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Authors:  Alessandra Carobbio; Guido Finazzi; Vittoria Guerini; Orietta Spinelli; Federica Delaini; Roberto Marchioli; Giovanna Borrelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

4.  Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.

Authors:  Anna Falanga; Marina Marchetti; Alfonso Vignoli; Donatella Balducci; Tiziano Barbui
Journal:  Exp Hematol       Date:  2005-05       Impact factor: 3.084

5.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Authors:  Tiziano Barbui; Alessandra Carobbio; Alessandro Rambaldi; Guido Finazzi
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

6.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.

Authors:  Roberto Marchioli; Guido Finazzi; Raffaele Landolfi; Jack Kutti; Heinz Gisslinger; Carlo Patrono; Raphael Marilus; Ana Villegas; Gianni Tognoni; Tiziano Barbui
Journal:  J Clin Oncol       Date:  2005-02-14       Impact factor: 44.544

7.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Authors:  Claire N Harrison; Peter J Campbell; Georgina Buck; Keith Wheatley; Clare L East; David Bareford; Bridget S Wilkins; Jon D van der Walt; John T Reilly; Andrew P Grigg; Paul Revell; Barrie E Woodcock; Anthony R Green
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

8.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

9.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

Review 10.  Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.

Authors:  Federico Lussana; Sabrina Caberlon; Chiara Pagani; Pieter W Kamphuisen; Harry R Büller; Marco Cattaneo
Journal:  Thromb Res       Date:  2009-03-18       Impact factor: 3.944
View more
  6 in total

1.  Comment on "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".

Authors:  Carlos Antonio Moura; Fabiana Santos Rosa; Luiz Henrique Assis; Carlos Geraldo Moura
Journal:  Drugs Aging       Date:  2021-04-19       Impact factor: 3.923

Review 2.  Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.

Authors:  Joan How; Amy Zhou; Stephen T Oh
Journal:  Ther Adv Hematol       Date:  2016-12-08

Review 3.  Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.

Authors:  Orly Leiva; Gabriela Hobbs; Katya Ravid; Peter Libby
Journal:  JACC CardioOncol       Date:  2022-06-21

Review 4.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

5.  Ruxolitinib for the Treatment of Essential Thrombocythemia.

Authors:  Arief Gunawan; Patrick Harrington; Natalia Garcia-Curto; Donal McLornan; Deepti Radia; Claire Harrison
Journal:  Hemasphere       Date:  2018-06-12

Review 6.  Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.

Authors:  Cecilia P Marin Oyarzún; Paula G Heller
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.